Calprotectin in acute infections and sepsis for prognosis, characterisation and diagnosis in the ED
08. Jun 2023 |
4 min read
Calprotectin in the Emergency Department (ED)
We are pleased to present results from a prospective clinical trial in collaboration with Charité – Universitätsmedizin Berlin and Labor Berlin. The results from the prospective CASCADE-trial (Calprotectin in acute infections and sepsis for prognosis, characterisation and diagnosis in the ED) were presented at the Innovation Theatre at ECCMID by the PI of the trial Dr. Wolfgang Bauer.
Gentian's plasma and serum calprotectin immunoassay GCAL® was used in the trial and showed high performance for detection of bacterial infection and prediction of sepsis and mortality. In conclusion calprotectin is a promising biomarker for detection of bacterial infection and sepsis, can be used for estimation of disease severity and guide clinical care and treatment decisions in the emergency department setting.
Watch the presentation now
In his presentation Dr. Bauer discusses the value of calprotectin for diagnosis and management of acute infections and sepsis in the ED.
Studies have shown the ability of calprotectin to predict bacterial infections before onset of clinical symptoms and distinguish between bacterial and viral infections, with high sensitivity and specificity. With early diagnosis of bacterial infections delayed treatment will be avoided as well as deterioration due to severe infections, including sepsis1-3.
Get in touch for more information and validation opportunities
Are you interested in adding GCAL® to your test menu, distribution or to discuss OEM opportunities for your company? Please fill out the form below or send us an email firstname.lastname@example.org.